345 related articles for article (PubMed ID: 10718827)
21. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults.
Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Shalet SM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):749-57. PubMed ID: 10468947
[TBL] [Abstract][Full Text] [Related]
22. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
Elgzyri T; Castenfors J; Hägg E; Backman C; Thorén M; Bramnert M
Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
24. Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.
Newman CB; Frisch KA; Rosenzweig B; Roubenoff R; Rey M; Kidder T; Kong Y; Pursnani A; Sedlis SP; Schwartzbard A; Kleinberg DL
J Clin Endocrinol Metab; 2011 Jan; 96(1):122-32. PubMed ID: 20926529
[TBL] [Abstract][Full Text] [Related]
25. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database.
Monson JP; Abs R; Bengtsson BA; Bennmarker H; Feldt-Rasmussen U; Hernberg-Stâhl E; Thorén M; Westberg B; Wilton P; Wüster C
Clin Endocrinol (Oxf); 2000 Sep; 53(3):281-9. PubMed ID: 10971444
[TBL] [Abstract][Full Text] [Related]
26. Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy.
Janssen JA; van der Toorn FM; Hofland LJ; van Koetsveld P; Broglio F; Ghigo E; Lamberts SW; Jan van der Lely A
Eur J Endocrinol; 2001 Dec; 145(6):711-6. PubMed ID: 11720895
[TBL] [Abstract][Full Text] [Related]
27. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults.
Giavoli C; Cappiello V; Corbetta S; Ronchi CL; Morpurgo PS; Ferrante E; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2004 Jul; 61(1):81-7. PubMed ID: 15212648
[TBL] [Abstract][Full Text] [Related]
28. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study.
Smith JC; Evans LM; Wilkinson I; Goodfellow J; Cockcroft JR; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2002 Apr; 56(4):493-501. PubMed ID: 11966742
[TBL] [Abstract][Full Text] [Related]
29. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
30. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
[TBL] [Abstract][Full Text] [Related]
32. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement.
Schneider HJ; Oertel H; Murck H; Pollmächer T; Stalla GK; Steiger A
Psychoneuroendocrinology; 2005 Jan; 30(1):29-37. PubMed ID: 15358440
[TBL] [Abstract][Full Text] [Related]
33. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
[TBL] [Abstract][Full Text] [Related]
34. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism.
Beshyah SA; Thomas E; Kyd P; Sharp P; Fairney A; Johnston DG
Clin Endocrinol (Oxf); 1994 Mar; 40(3):383-91. PubMed ID: 8187303
[TBL] [Abstract][Full Text] [Related]
35. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
[TBL] [Abstract][Full Text] [Related]
36. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
[TBL] [Abstract][Full Text] [Related]
37. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
[TBL] [Abstract][Full Text] [Related]
38. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults.
al-Shoumer KA; Gray R; Anyaoku V; Hughes C; Beshyah S; Richmond W; Johnston DG
Clin Endocrinol (Oxf); 1998 Jun; 48(6):795-802. PubMed ID: 9713570
[TBL] [Abstract][Full Text] [Related]
39. Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy.
Golgeli A; Tanriverdi F; Suer C; Gokce C; Ozesmi C; Bayram F; Kelestimur F
Eur J Endocrinol; 2004 Feb; 150(2):153-9. PubMed ID: 14763913
[TBL] [Abstract][Full Text] [Related]
40. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults.
Beshyah SA; Freemantle C; Shahi M; Anyaoku V; Merson S; Lynch S; Skinner E; Sharp P; Foale R; Johnston DG
Clin Endocrinol (Oxf); 1995 Jan; 42(1):73-84. PubMed ID: 7889635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
